跳至主要内容
临床试验/NCT06248957
NCT06248957招募中不适用

SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION

Karolinska Institutet1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2024年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
500
试验地点
1
主要终点
control of immune dysregulation

研究概览

简要总结

The aim of the SAID study is to create a national resource in Sweden to enable comprehensive immunological analyses of an extremely complex and clinically challenging group of individuals with variable forms of immune system dysregulation. We hope to establish a biobank of primarily blood and fecal samples from children and adults, with confirmed or suspected immune dysregulation, as well as age- and sex- matched healthy controls, for comparisons of immune cell/mediator alongside various clinical presentations of these immunological diseases as well as microbiome samples as possible a possible modifier of clinical presentations. The project will also include the establishment of a national database with deep immunological data, treatment and clinical outcomes for these patients, accessible to participating researchers and clinicians.

详细描述

BACKGROUND

Immune dysregulation encompasses multiple different conditions in which the immune system does not function properly and displays inappropriate or inadequate responses, overreactions or under-reactions directed towards external or internal targets. It is a broad term, and its manifestations include several different categories of disease:

Immunodeficiencies: These disorders impair the immune system's ability to defend the body against foreign or abnormal cells that invade or attack it (such as bacteria, viruses, fungi, and cancer cells). As a result, unusual bacterial, viral, or fungal infections or lymphomas or other cancers may develop. Primary immunodeficiencies (PIDs) comprise a group of nearly 500 inherited disorders, often due to single-gene mutations that result in the specific impairments in immune function. Secondary immunodeficiencies (SIDs) involve a weakened immune system caused by external sources e.g. chemical (chemotherapy), infection (HIV) or cancer.

Autoimmune Disorders: In these conditions the production of autoantibodies against self-antigens causes the immune system to attack healthy cells and tissues. Some of the most common examples include type 1 diabetes (T1D), rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus erythematosus (SLE).

Autoinflammatory Disorders: Here dysregulation of the innate immune system leads to spontaneous and recurrent inflammatory episodes. In contrast to autoimmune diseases where antibodies against self-antigens play a central role, the defect in autoinflammatory diseases often lies in the first responder, innate, arm of the immune system where the defect triggers inappropriate activation of the normal inflammatory response or disables resolution thereof. Examples include familial Mediterranean fever (FMF) and cryopyrin-associated periodic syndromes.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients of all ages seeking care or being referred for suspected immune dysregulation or with a known immune-mediated disease and failing to respond to standard therapy

排除标准

  • Healthy control individuals will be excluded on the basis of having a diagnosis of an immune mediated disorder, immunomodulatory treatment or current infection or cancer.

结局指标

主要结局

control of immune dysregulation

时间窗: 1-3 months from start of therapy

Remission and control of immune dysregulation manifested as reduced inflammation, symptom relieve and halted immunoproliferation for examples

次要结局

  • Exploratory immunological parameters(1-3 months from start of therapy)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Petter Brodin

M.D., Ph.D., Professor

Karolinska Institutet

研究点 (1)

Loading locations...

相似试验